Showing results (91-100 of 224) with videos related to
Sort By:
Pageof 23
Frontiers in Endocrinology|October 26, 2019
Sleep Deprivation Alters the Pituitary Stress Transcriptome in Male and Female MiceMario G Oyola, Elizabeth A Shupe, Anthony R Soltis, et al.American Journal of Otolaryngology|November 5, 2020
Decreased overall survival in black patients with HPV-associated oropharyngeal cancerSiddharth Sheth, Douglas R Farquhar, Nicholas R Lenze, et al.Cancer Discovery|October 1, 2013
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumorsEsra A Akbay, Shohei Koyama, Julian Carretero, et al.Plos One|October 3, 2013
The LKB1 tumor suppressor as a biomarker in mouse and human tissuesYuji Nakada, Thomas G Stewart, Christopher G Peña, et al.Cancers|June 28, 2023
Unsupervised Hierarchical Clustering of Head and Neck Cancer Patients by Pre-Treatment Plasma Metabolomics Creates Prognostic Metabolic SubtypesRonald C Eldridge, Zhaohui S Qin, Nabil F Saba, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancerCarrie B Lee, Thomas E Stinchcombe, Dominic T Moore, et al.Nature Communications|January 13, 2021
SCISSOR: a framework for identifying structural changes in RNA transcriptsHyo Young Choi, Heejoon Jo, Xiaobei Zhao, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2008
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancerThomas E Stinchcombe, David E Morris, Carrie B Lee, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 22, 2022
Characterization of Epigenomic Alterations in HPV16+ Head and Neck Squamous Cell CarcinomasAnders Berglund, Clarisse Muenyi, Erin M Siegel, et al.Cureus|May 12, 2026
Survival and Quality of Life After Reirradiation With Concurrent Pemetrexed/Erlotinib Followed by Maintenance Erlotinib for Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma: Final Report of a Phase I/II TrialRyan T Hughes, Sydney Smith, D Neil Hayes, et al.Pageof 23